GSK plc (GSK.L)
| Previous close | 1,459.50 |
| Open | 1,470.00 |
| Bid | 1,477.00 x 0 |
| Ask | 1,477.50 x 0 |
| Day's range | 1,465.62 - 1,486.73 |
| 52-week range | 1,371.40 - 1,823.50 |
| Volume | |
| Avg. volume | 7,082,051 |
| Market cap | 60.267B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 13.08 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.60 (4.11%) |
| Ex-dividend date | 15 Aug 2024 |
| 1y target est | N/A |
- Bloomberg
Sanofi, GSK, CSL Tapped to Expand US Bird Flu Vaccine Supply
(Bloomberg) -- GSK Plc, Sanofi and CSL Ltd. secured $72 million from the US government to ramp up production of bird flu vaccines as a nationwide outbreak among livestock and poultry has led to several human infections that have raised concerns about further spread.Most Read from BloombergSingapore Ends 181 Years of Horse Racing to Make Way for HomesWhat Do US Vehicle Regulators Have Against Tiny Cars?For a Master of Brutalist Provocations, a Modest Museum AppraisalMexico City Restricts Airbnb R
- Insider Monkey
GSK plc (NYSE:GSK) Doesn’t Rank Too High In The List Of The Best Global Stocks To Buy
We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where GSK plc (NYSE:GSK) ranks among the top ten global stocks to buy. With the third quarter of 2024 ending, the discourse on the stock market for global equities has shifted back to interest […]
- Simply Wall St.
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with a significant decline in U.S. vaccine sales and ongoing legal issues. In the discussion that follows, we will delve into GSK's financial health, operational inefficiencies, strategic growth initiatives, and external threats to provide a comprehensive overview of the company's current business situation.
